HK Stock Market Move | ASCLETIS-B (01672) rose by over 4%, completing the enrollment of subjects in the ASC30 clinical trial for the treatment of obesity in the United States Phase IIa study.

ASCLETIS-B(01672) rose more than 4%, at the time of publication, it rose 4.18% to 9.47 Hong Kong dollars, with a turnover of 2.6558 million Hong Kong dollars. In terms of news, Ge Li Pharmaceutical announced this morning that the Phase IIa study of its small molecule GLP-1 receptor agonist ASC30, a once-monthly subcutaneous depot formulation for the treatment of obesity (NCT06679959) in the United States has recently completed subject enrollment. The 65 subjects are all obese or overweight individuals with at least one weight-related comorbidity. The Phase IIa study of ASC30, a once-monthly subcutaneous depot formulation for the treatment of obesity, is being conducted in the United States, lasting 12 weeks, randomized, double-blind, placebo-controlled, and multicenter clinical research, aimed at evaluating its safety, tolerability, and efficacy in obese subjects (body mass index (BMI) 30 kg/m2) or overweight subjects with at least one weight-related comorbidity (27 kg/m2 BMI < 30 kg/m2). The study is divided into three cohorts with different doses, totaling 65 subjects. Topline data is expected to be available in the first quarter of 2026.